Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Bevacizumab 35Paclitaxel 31Carboplatin 24pembrolizumab 23Specimen Handling 21Magnetic Resonance Spectroscopy 19Gemcitabine 18olaparib 16liposomal doxorubicin 16Cyclophosphamide 15fludarabine 12Topotecan 12Biopsy 12niraparib 11Cisplatin 10Taxes 8Nivolumab 8Immunoglobulin G 8Fulvestrant 8Disulfides 8Doxorubicin 7aldesleukin 6Surveys and Questionnaires 6palbociclib 5Oxaliplatin 5Fluorouracil 5trastuzumab deruxtecan 4oregovomab 4mirvetuximab soravtansine 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × RC48 antibody × 90 days × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡